Dr. Frederic Moll is the CEO of PROCEPT BioRobotics Corporation and has had quite an impressive journey in the field of medicine and medical technology. With a medical degree from Stanford University and a background in biology from UC Berkeley,...

Dr. Frederic Moll is the CEO of PROCEPT BioRobotics Corporation and has had quite an impressive journey in the field of medicine and medical technology. With a medical degree from Stanford University and a background in biology from UC Berkeley, he has dedicated his career to advancing healthcare solutions. Before leading PROCEPT, he co-founded Auris Health, where he served as CEO, helping innovate robotic surgical systems before Johnson & Johnson acquired the company. Dr. Moll also held significant roles in various healthcare companies, showcasing his deep expertise. What’s interesting is that in 2023, his total compensation reached an impressive $25.7 million, driven by a large stock vesting and bonus payouts tied to company performance. Under his leadership, PROCEPT is focused on creating advanced robotics solutions for treating prostate conditions. His ability to lead and innovate in a cutting-edge field distinguishes him in the tech and healthcare industries.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other PROCEPT BioRobotics Corporation CEOs

P

Dr. Frederic Moll

Founder and Ex-CEO of PROCEPT BioRobotics Corporation

Education

M.D. from Stanford University; B.S. in Biology from the University of California, Berkeley.

Field of Expertise

Healthcare & Life Sciences - Medicine

Sector of Economy

Healthcare

Born

September 1, 1958 - 66 years ago

CEO of PROCEPT BioRobotics Corporation for

2 years 8 months (Oct 2021 - Jul 2024)

Previous Experience

Co-founder and CEO of several medical device companies including Intuitive Surgical and Hansen Medical.

Rivals

Competitors/colleagues of Dr. Frederic Moll

Holdings

See how much did Dr. Frederic Moll make over time.

Dr. Frederic Moll holds a significant position in PROCEPT BioRobotics, showcasing his commitment to the company. His holdings have seen major fluctuations, with a peak worth around $1.4 million in 2023 from options and stocks. In 2021, his wealth was...

Dr. Frederic Moll holds a significant position in PROCEPT BioRobotics, showcasing his commitment to the company. His holdings have seen major fluctuations, with a peak worth around $1.4 million in 2023 from options and stocks. In 2021, his wealth was substantially lower, around $182,445, indicating a rapid growth in value as the company evolved. This rapid wealth increase corresponds with his role in developing advanced technologies in medical robotics, highlighting the potential of the medtech industry. His holdings reflect a blend of vested shares and options, proving alignment with shareholder interests as the company continues to thrive.

Total Stock Sold

$3.05M

PRCT

$3.05M

79,000 PRCT shares

What if they kept their stock?

If Dr. Frederic Moll didn't sell their stock, today they would have:
Extra PRCT79,000 shares worth $3.31M.
This is 8.6% and $262.28K more than what they got when they sold the stock.

Insider Trading

See recent insider trades of Dr. Frederic Moll.

PRCT

1,376 shares

PRCT

Jun 4, 2024

Received

PRCT

$3.07M

PRCT at $38.87/share

Dec 6, 2023

Sale

PRCT

2,711 shares

PRCT

Jun 15, 2023

Received

PRCT

$75.00K

PRCT at $37.48/share

Jun 7, 2022

Received

PRCT

$10.00M

PRCT at $25.00/share

Sep 17, 2021

Purchase

VERO

145,394 shares

VERO

Nov 7, 2019

Received

Compensation History

See how much did Dr. Frederic Moll make over time.

Dr. Moll's compensation reflects his leadership role at PROCEPT BioRobotics. In 2023, he earned a total of $25.7 million, which included a base salary of $612,575 and a notable cash bonus of $512,730 linked to exceeding performance goals. The bulk of his compensation came from stock options and restricted stock units that vested during the year, putting his vested stocks value at around $25.7 million. This structure aligns his interests with those of shareholders, ensuring that as the company does well, he benefits significantly. In comparison, his total compensation in 2022 was about $1.26 million, showing a significant increase as the company matured. This demonstrates how performance metrics, like revenue targets and operational efficiencies, drive substantial rewards for top executives at successful companies.

Year

2023

Total Compensation

$26.85M

Salary

$612.58K

Board Justification

The compensation philosophy is to align the interests of executives with stockholder interests, attract and retain talent, and reward performance that contributes to the company's success.

Bonus

$512.73K

Board Justification

Cash bonus payout of 83.7% of target based on performance metrics for the year 2023.

Other

$0.00

Board Justification

No other compensation reported for 2023.

Restricted Stock

$25.72M(119.33K RSU)

Board Justification

RSUs that vested in 2023, with a total of 119,332 shares.

Performance Metrics

Performance metrics included revenue targets, U.S. procedures completed, and adjusted EBITDA.

Other PROCEPT BioRobotics Corporation CEOs

Here are other CEOs of PROCEPT BioRobotics Corporation

Mr. Thomas M. Prescott

CEO of PROCEPT BioRobotics Corporation

July 2024 - Present